Isotretinoin and the Risk of Depression in Patients With Acne Vulgaris: A Case-Crossover Study
J Clin Psychiatry 2008;69(4):526-532
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: To determine whether isotretinoin increases the
risk of depression in patients with acne vulgaris.
Method: A case-crossover study was performed among subjects
who received >= 1 isotretinoin prescription from 1984 through 2003. Data were
obtained from the Régie de l'Assurance Maladie du Québec (RAMQ) and Quebec's
hospital discharge (Med-Écho) administrative databases. Cases were defined as
those with a first diagnosis or hospitalization for depression (ICD-9 codes:
296.2, 298.0, 300.4, 309.0, 309.1, and 311) during the study period (1984-2003)
and those who filled a prescription for an antidepressant in the 30 days
following their diagnosis or hospitalization. The index date was the calendar
date of the diagnosis or hospitalization for depression. Cases were covered by
the RAMQ drug plan and had >= 1 acne diagnosis in the 12 months prior to the
index date. Those who received an antidepressant in 12 months prior to the
index date were excluded. Exposure to isotretinoin in a 5-month risk period
immediately prior to the index date was compared to a 5-month control period.
Relative risks along with 95% CIs were estimated using conditional logistic
Results: Of the 30,496 subjects in the initial cohort, 126
(0.4%) cases met inclusion criteria. The crude relative risk for those exposed
to isotretinoin was 2.00 (95% CI = 1.03 to 3.89). After adjusting for potential
time-dependent confounders, the relative risk for those exposed to isotretinoin
was 2.68 (95% CI = 1.10 to 6.48).
Conclusion: This is the first controlled study to find a
statistically significant association between isotretinoin and depression.
Because depression could have serious consequences, close monitoring of
isotretinoin users is indicated.